6 years ago

Biosignatures Secures £3.5 Million to Develop Blood Tests for Cancers and Dementias

  • Biosignatures, a UK-based diagnostic technology company focused on blood tests, has raised £3.5 million in funding led by ADV

  • The company is using the funds to develop 20 novel diagnostic screening tests for cancers and dementias, all of which can be performed on a single blood sample

  • Biosignatures has developed a machine learning system, along with a sample measurement system, to discover new clinical diagnostic tests.

      • ProblemHealthcare

      "Discovering new clinical diagnostic tests is expensive and time-consuming, with many blood tests still relying on outdated methods."

      Solution

      "Biosignatures is using machine learning to analyse vast amounts of data from biobanks, making the process of discovering new blood tests faster and more cost-effective. They aim to develop 20 novel diagnostic screening tests for cancers and dementias."

      Covered on